Phase 3Completed

Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk (AMG145)

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) on LDL-C in Combination With Statin Therapy in Japanese Subjects With High Cardiovascular Risk and With Hyperlipidemia or Mixed Dyslipidemia

Sponsor
Amgen (Industry)
Enrollment
409 enrolled
Conditions
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Interventions
Atorvastatin; Evolocumab; Placebo to Evolocumab
Ages
adults, older adults
Registry
NCT01953328

Full record on ClinicalTrials.gov

From the registry

The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous evolocumab administered every 2 weeks and once a month, compared with placebo, on percent change from baseline in LDL-C when used in combination with statin therapy in adults with high cardiovascular risk and with hyperlipidemia or mixed dyslipidemia.

Primary outcomes

  • Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12
  • Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

History

  1. Results first posted

  2. Last registry update

  3. Primary completion

  4. Started

  5. Registered